Etrinabdione
As of the edition of 20 October 2026, Etrinabdione is a small molecule: in active development; acts on CNR2 and PPARG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Small molecule
- Registered trials
- 3, 0 stopped early
- Disease areas
- Heart and blood vessels; Immune system; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Etrinabdione.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 0 | 1 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Emerald Health Pharmaceuticals | Lead sponsor of trials | 2018 to now |
| VivaCell Biotechnology España | Lead sponsor of trials | 2026 to now |